Compare AbbVie Inc (ABBV) vs Ally Financial Inc (ALLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Ally Financial Inc — how do they compare? AbbVie Inc trades at $253.61 (market cap $449.91B), while Ally Financial Inc trades at $44.12 (market cap $13.92B). The key difference: AbbVie Inc is far larger — about 32.3× Ally Financial Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | ALLY | |
|---|---|---|
Market Cap | $449.91B | $13.92B |
Sector | Health | Financials |
52-Week High | $261.07 | $47.25 |
52-Week Low | $184.85 | $35.96 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
Ally Financial (ALLY) trades at $45.40, up 0.18% with strong analyst support (68% buy ratings) and a $54 consensus price target. The stock shows bullish technical momentum with recent earnings beats in Q3 2025-Q1 2026. Fundamentals remain solid with a P/E of 11.22 and net income margin of 14.9%, though revenue has declined from $9.2B in 2022 to $8.77B in 2025. Recent corporate developments include a $0.30 dividend payment and upcoming Q2 2026 earnings release on July 21, 2026.
ALLY presents a compelling value opportunity with attractive valuation metrics and consistent earnings outperformance. The primary investment thesis centers on the company's dominant auto lending position and shareholder returns via dividends. Key risks include revenue stagnation, macroeconomic sensitivity to interest rates, and competitive pressure from digital banking disruptors. Upside potential exists if Q2 2026 earnings meet or exceed the $1.26 EPS estimate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →
